Viewing Study NCT01735968


Ignite Creation Date: 2025-12-24 @ 6:25 PM
Ignite Modification Date: 2026-01-25 @ 6:07 AM
Study NCT ID: NCT01735968
Status: COMPLETED
Last Update Posted: 2020-12-21
First Post: 2012-11-15
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None 3rd Line GIST View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Imatinib mesylate View
None STI571 View
None BYL719 View
None GIST View
None 3rd line GIST View